Bartlett & Co’s Neurocrine Biosciences NBIX Stock Holding History

Bartlett & Co’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5	Closed	–	–	1018
2021 Q2	$0	Hold	5	–	–	﹤0.01%	1053
2021 Q1	$0	Hold	5	–	–	﹤0.01%	1130
2020 Q4	$0	Buy	+5	New	+$483	﹤0.01%	1178

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Bartlett & Co's NBIX Position: Q3 2021 in Review

Bartlett & Co sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 5 shares.

Bartlett & Co first reported a position in NBIX in Q4 2020 and held it in 3 quarters. The position peaked at $0 in Q2 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

Bartlett & Co reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
Bartlett & Co sold 5 Neurocrine Biosciences shares in Q3 2021.
Bartlett & Co first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 3 quarters.
Bartlett & Co's Neurocrine Biosciences position peaked at $0 in Q2 2021.
395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Bartlett & Co's 13F filing for Q3 2021, filed 15 Oct 2021.